Skip to content
Screener

Merck & Co. MRK Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Zoetis logo
ZoetisZTS
$1.88B+9.4%
Pfizer logo
PfizerPFE
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$16.6B+5.1%
Gross profit$12.2B-0.3%
Net income-$1.3B-130%
EPS (diluted)-$0.54-131%

Balance sheet

See full
Cash & equivalents$6.9B-14.6%
Total debt$56.7B+54.0%
Total equity$41.9B-14.4%
Total assets$129.80B+10.4%

Cash flow

See full
Operating cash flow$5.4B+63.1%
CapEx$893.0M+16.9%
Free cash flow$4.5B+77.0%

Valuation

See full
Market cap$317.57B+57.6%
Enterprise value$367.4B+59.5%
P/E100.1×+87.8×
P/S4.8×+1.6×

Profitability

See full
Gross margin73%-3.6pp
Net margin4.8%-21.0pp
FCF margin24.1%+1.0pp

Returns & leverage

See full
Return on equity7%-28.5pp
Debt / equity1.4×+0.6×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Merck & Co.’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:15 PM EST
Fiscal year
FY2026
Accession
0000310158-26-000063
Line item2025 / Gross Carrying Amount2025 / Accumulated Amortization2025 / Net2024 / Gross Carrying Amount2024 / Accumulated Amortization2024 / Net
Product rights$42,038$20,710$21,328$29,988$19,066$10,922
IPR&D427427430430
Trade names2,8811,1581,7232,8819541,927
Licenses and other10,0646,8613,2038,8635,7723,091
$55,410$28,729$26,681$42,162$25,792$16,370

Item 8.Financial Statements and Supplementary Data.

FAQ

What is Merck & Co.'s finite-lived intangible assets, accumulated amortization?
Merck & Co. (MRK) reported finite-lived intangible assets, accumulated amortization of $28.73B in Q4 2025.
How has Merck & Co.'s finite-lived intangible assets, accumulated amortization changed year-over-year?
Merck & Co.'s finite-lived intangible assets, accumulated amortization increased by 11.4% year-over-year, from $25.79B to $28.73B.
What is the long-term trend for Merck & Co.'s finite-lived intangible assets, accumulated amortization?
Over 5 years (2020 to 2025), Merck & Co.'s finite-lived intangible assets, accumulated amortization has grown at a 8.5% compound annual growth rate (CAGR), from $19.14B to $28.73B.
What does finite-lived intangible assets, accumulated amortization mean?
Finite-Lived Intangible Assets, Accumulated Amortization

Ask your AI about Merck & Co.'s finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude